Effect of Metoclopramide Versus Sumatriptan for Emergency Department Treatment of Migraine Headache
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01791400 |
Recruitment Status :
Completed
First Posted : February 15, 2013
Last Update Posted : February 15, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Migraine Disorders | Drug: metoclopramide, injection,20mg, one time Drug: Sumatriptan, injection, 6 mg, one time | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 124 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Study of Effects of Metoclopramide Versus Sumatriptan on Migraine Headache |
Study Start Date : | July 2009 |
Actual Primary Completion Date : | November 2010 |
Actual Study Completion Date : | November 2010 |

Arm | Intervention/treatment |
---|---|
sumatriptan
Patients who underwent 6 mg sumatriptan subcutaneous one time
|
Drug: Sumatriptan, injection, 6 mg, one time
Sumatriptan, subcutaneous injection, 6 mg, one time |
Metoclopramide
Patients who underwent 20 mg Metoclopramide intravenous one time
|
Drug: metoclopramide, injection,20mg, one time
metoclopramide, intravenous injection,20mg, one time
Other Name: plasil |
- pain [ Time Frame: at one hour after prescription ]determining pain in Metoclopramide versus sumatriptan groups

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- 20-60 years old and presented with acute headache similar to previous episodes,
- with or without phonophobia,
- photophobia,
- vomiting or nausea.
Exclusion Criteria:
- fever or neck stiffness,
- altered mental state,
- pregnancy,
- recent trauma or seizure (within 24 hours),
- focal neurological abnormality on physical examination,
- allergy to metoclopramide,
- hypertension,
- cardiovascular diseases.
Also if the patients had taken a triptan or ergot during the last 24 hours were excluded from the study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01791400
Iran, Islamic Republic of | |
Al-zahra university hospital | |
Isfahan, Iran, Islamic Republic of |
Principal Investigator: | babak masoumi, A.Professor | Isfahan, Isfahan, Iran, Islamic Republic of |
Responsible Party: | Hamidreza Shemshaki, Research Assistant, Isfahan University of Medical Sciences |
ClinicalTrials.gov Identifier: | NCT01791400 |
Other Study ID Numbers: |
ASD-1213-70 |
First Posted: | February 15, 2013 Key Record Dates |
Last Update Posted: | February 15, 2013 |
Last Verified: | February 2013 |
Metoclopramide Sumatriptan migraine headache |
Sumatriptan Migraine Disorders Headache Headache Disorders, Primary Headache Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Pain Neurologic Manifestations Metoclopramide Vasoconstrictor Agents Serotonin 5-HT1 Receptor Agonists |
Serotonin Receptor Agonists Serotonin Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Antiemetics Autonomic Agents Peripheral Nervous System Agents Gastrointestinal Agents Dopamine D2 Receptor Antagonists Dopamine Antagonists Dopamine Agents |